Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Dr Gonzalez-Martin on the Efficacy of TUB-040 in Ovarian Cancer

December 3rd 2025

Antonio Gonzalez-Martin, MD, discusses the key efficacy findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Dr Bellmunt on Future Directions With ctDNA-Guided Immunotherapy in Urothelial Cancer

December 3rd 2025

Joaquim Bellmunt, MD, PhD, discusses future research directions with ctDNA-guided immunotherapy in urothelial cancer.

Dr Jänne on the Design of the FLAURA2 Trial of Osimertinib Plus Chemotherapy in EGFR+ NSCLC

December 3rd 2025

Pasi A. Jänne, MD, PhD, discusses the design of the FLAURA2 trial in EGFR+ NSCLC.

Maintenance Fuzuloparib Displays PFS Benefit in Newly Diagnosed, Advanced Ovarian Cancer

December 3rd 2025

Fuzuloparib extended PFS vs placebo regardless of the addition of apatinib in newly diagnosed advanced ovarian cancer.

Lutetium Lu 177 Vipivotide Tetraxetan Shows Activity in Oligometastatic HSPC

December 2nd 2025

Lutetium Lu 177 vipivotide tetraxetan was effective in patients with oligometastatic hormone-sensitive prostate cancer.

Updated Cosibelimab Label Reflects Long-Term Data in Advanced CSCC

December 2nd 2025

The prescribing information for cosibelimab in advanced cutaneous squamous cell carcinoma was updated to include long-term data from the CK-301-101 trial.

IGV-001 Prolongs OS vs Placebo in Newly Diagnosed Glioblastoma

December 2nd 2025

IGV-001 produced an OS benefit vs placebo in newly diagnosed glioblastoma.

sNDA for Aminolevulinic Acid Gel Plus PDT in sBCC Is Submitted to the FDA

December 2nd 2025

Biofrontera has submitted a sNDA to the FDA seeking the approval of aminolevulinic acid gel plus PDT in sBCC.

Subcutaneous Pembrolizumab Approved in EU for All Adult Indications

December 1st 2025

Pembrolizumab obtained approval from the European Commission for subcutaneous administration for all adult indications.

CLN-049 Nets FDA Fast Track Designation in Relapsed/Refractory AML

December 1st 2025

The FDA granted fast track designation to CLN-049 for relapsed/refractory acute myeloid leukemia.

FDA Approves IsoPSA Blood-Based Prostate Cancer Test as Diagnostic Aid for High-Risk Disease

December 1st 2025

IsoPSA has been FDA approved for use as an aid in the diagnosis of high-grade prostate cancer in men at least 50 years of age with elevated PSA levels.

ctDNA and MRD Advance Toward Clinical Integration in Lymphoma

December 1st 2025

Sarah Rutherford, MD, discusses emerging roles for ctDNA and MRD in lymphoma, highlighting surveillance value, personalized assays, and evolving adoption.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Dr Freedland on the Increasingly Prominent Role of Enzalutamide in Prostate Cancer Treatment

December 1st 2025

Stephen Freedland, MD, discusses how findings from the phase 3 EMBARK trial suggest a new standard of care in prostate cancer.

Dr Desai on the Use of JAK Inhibitors in Myeloproliferative Neoplasms

November 28th 2025

Ruchi J. Desai, MD, discusses the current standing of JAK inhibitors in the treatment landscape of myeloproliferative neoplasms.

Dr Smith on Future Research Directions in Prostate Cancer

November 28th 2025

Matthew R. Smith, MD, PhD, discusses what the future of prostate cancer research may look like.

Dr Jakubowiak on the Efficacy of KRd Maintenance Therapy Post-ASCT in Multiple Myeloma

November 28th 2025

Andrzej Jakubowiak, MD, PhD, discusses efficacy data with maintenance KRd after ASCT in multiple myeloma.

Dr Bellmunt on Adjuvant Atezolizumab in Patients With MIBC Who Were ctDNA+ After Initial Testing

November 28th 2025

Joaquim Bellmunt, MD, PhD, discusses subgroup and safety data from the phase 3 IMvigor011 trial in patients with MIBC.

Dr Gonzalez-Martin on the NAPISTAR1-01 Trial of TUB-040 in Ovarian Cancer

November 28th 2025

Antonio Gonzalez-Martin, MD, discusses the design of the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Dr Randall on the Importance of Addressing Socioeconomic Disparities to Improve Sarcoma Survivorship

November 27th 2025

R. Lor Randall, MD, FACS, discusses the potential implications of research into how socioeconomic disparities and cancer biology impact long-term outcomes in pediatric sarcoma.